StockData
Lipella Pharmaceuticals Inc. logo

Lipella Pharmaceuticals Inc. (LIPO) stock

LIPOOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2025, quý kết thúc ngày Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 6/30
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $2.27KP/E –Yield –

Lipella Pharmaceuticals Inc. saw revenue fall 19.4% to $389.78K over the twelve months to Sep 30, 2025. At the latest close the market valued the company at $2.27K.

Revenue
$389.78K
-19.4% vs. a year earlier
Operating income
-$5.41M
TTM Q3 2025
EPS, diluted
-$2.42
TTM Q3 2025

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2025

Valuation

Market cap
$2.27K
P/E ratio
–
Price to sales
0.01
Price to book
0.00
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$389.78K
Net income
-$5.33M
EPS, diluted
-$2.42
Book value per share
$0.33
Diluted shares
5M

Trading

Previous close
$0.00
Open
$0.00
Day's range
$0.00 – $0.00
Volume
0
Average volume (20 days)
1,506

Market cap history

Month-end market cap since 2022, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodLIPOS&P 500DifferenceLIPO per yearS&P 500 per year
1 month0.0%+0.6%−0.6 pts
3 months-98.5%+3.4%−101.8 pts
Year to date-99.7%+13.3%−113.0 pts
1 year-99.9%+16.6%−116.5 pts
3 years-100.0%+86.4%−186.4 pts-96.6%+23.1%

Five years at a glance

Fiscal years 2020 to 2024 and trailing twelve months, USD

Revenue

$389.78K-19.4% YoY

Operating income

-$5.41M

Net income

-$5.33M

EPS, diluted

-$2.42

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Lipella Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Lipella Pharmaceuticals

Pharmaceutical Preparations

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing therapies by reformulating existing generic active pharmaceutical ingredients. The company utilizes a proprietary metastable liposome drug delivery platform designed for local drug application to body cavities lined with endothelial and mucosal surfaces. Its product pipeline includes LP-10 for the treatment of hemorrhagic cystitis, LP-310 for oral lichen planus, LP-410 for oral graft-versus-host disease, and LP-50 for non-muscle invasive bladder cancer. These candidates target patients suffering from severe inflammatory mucosal conditions and treatment-related complications.

Company profile, executives and history

Lipella Pharmaceuticals stock: common questions

What is Lipella Pharmaceuticals's stock price?

LIPO closed at $0.00 on Oct 19, 2026, up 0.00% on the day.

What is Lipella Pharmaceuticals's market cap?

Lipella Pharmaceuticals was worth $2.27K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is LIPO's P/E ratio?

Lipella Pharmaceuticals lost money over the twelve months to Sep 30, 2025 (diluted EPS -$2.42), so it has no meaningful P/E ratio.

How much revenue does Lipella Pharmaceuticals make?

Lipella Pharmaceuticals reported revenue of $389.78K for the twelve months to Sep 30, 2025, down 19.4% from a year earlier.

Does Lipella Pharmaceuticals pay a dividend?

No. Lipella Pharmaceuticals has not paid a cash dividend over the last twelve months.

How has LIPO stock performed over the past year?

Including dividends, LIPO returned -99.9% over the past year, against +16.6% for the S&P 500.

Who are Lipella Pharmaceuticals's competitors?

Companies most similar to Lipella Pharmaceuticals by business, industry and size include CANF, SCNX, RGBP, PVCT, RDHL.

See a number that looks wrong?